Modality
Bispecific Ab
MOA
GLP-1/GIP
Target
SOS1
Pathway
JAK/STAT
MigraineNarcolepsyLGS
Development Pipeline
Preclinical
~Nov 2012
→ ~Feb 2014
Phase 1
~May 2014
→ ~Aug 2015
Phase 2
~Nov 2015
→ ~Feb 2017
Phase 3
May 2017
→ Apr 2026
Phase 3Current
NCT06453865
1,643 pts·LGS
2017-05→2026-04·Active
1,643 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-04-162w awayPh3 Readout· LGS
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
P3
Active
Catalysts
Ph3 Readout
2026-04-16 · 2w away
LGS
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06453865 | Phase 3 | LGS | Active | 1643 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| Fixaosocimab | TG Therapeutics | Phase 2/3 | SOS1 | |
| Zanurapivir | Immunocore | Phase 1 | SOS1 |